Leon O. Moulder Jr., Chief Executive Officer at Zenas BioPharma, Inc. (ZBIO), bought 60,000 shares at $18.02 ($1.1M) on 2026-04-28, disclosed to the SEC on 2026-04-29.
CEO Leon O. Moulder Jr. executed the largest insider purchase in Zenas BioPharma's history by buying 25,000 shares at $18.02, signaling confidence during a period of significant stock volatility. This move coincides with a 16% decline over the last 90 days, potentially offering a contrarian entry point for investors betting on the company's pipeline execution.
Zenas BioPharma is currently trading at $17.54, down 12.61% over the past five days and 16.0% over the last 90 days. The stock remains roughly 60.67% below its 52-week high of $44.60.
The company secured a $250 million non-dilutive loan on March 17 to support the commercialization of obexelimab and further pipeline development. Additionally, two other insiders purchased shares in the last 30 days, creating a cluster of insider buying activity.
The stock carries a high short interest of 26.1%, which could exacerbate volatility if the price rallies. Additionally, the company reported a Q1 2026 net loss of $80.99 million and an EPS loss of $1.46, highlighting ongoing financial pressure.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.02 | 25,000 | $451K | 42.2% |
| 2 | $17.62 | 35,000 | $617K | 57.8% |
| Total | $17.79 avg | 60,000 | $1.1M | 100% |
| Filing → |
| ZBIO | BUY | 2026-02-03 | $1.0M | — | Filing → |
| ZBIO | BUY | 2026-01-09 | $1.6M | — | Filing → |
| ZBIO | BUY | 2025-10-09 | $1.5M | — | Filing → |